The US psychedelic industry is at a pivotal moment, moving gradually from clinical trials into early stages of commercialization, but still facing regulatory and societal hurdles. Companies are promising breakthroughs that target the root causes of mental health conditions like depression, potentially enabling limited-dose treatments that could ease pressure on…
Broadcom Inc (NASDAQ: AVGO) continues to struggle as China vowed “resolute and forceful” measures after the US raised its…
London has witnessed the departure of more super-wealthy residents than any city in the world, apart from Moscow, according…
US wine sellers are concerned about President Donald Trump’s tariffs which are set to take effect later on Wednesday.…
Trump tariffs, an escalating trade war, and the related concerns of a recession before the end of this year…
Asian stocks staged a recovery on Tuesday, rebounding from 18-month lows as markets caught their breath following a period…
Apple continues to face a massive stock slump, with its market capitalization shrinking by nearly $640 billion over the…
Levi Strauss & Co (NYSE: LEVI) shares are gaining after the jeans company said it was leaving its guidance…
China has issued a stern warning to the United States, condemning threats to escalate tariffs and pledging to retaliate…